PCN131 COST EFFECTIVENESS OF PEMETREXED IN COMBINATION WITH PEMBROLIZUMAB AND PLATINUM CHEMOTHERAPY (PEM+PEMBRO+PLAT), FOR INITIAL TREATMENT OF PATIENTS WITH METASTATIC NON-SQUAMOUS (NSQ) NON-SMALL CELL LUNG CANCER (NSCLC) IN THE U.S

Autor:	L.J. Smolen, C.E. Muehlenbein, Katherine B. Winfree, H. Aggarwal, S. Perk, C.A. Bly, T. Klein, Y. Zhu
Rok vydání:	2019
Předmět:	Oncology medicine.medical_specialty Cost effectiveness business.industry Health Policy Public Health Environmental and Occupational Health non-small cell lung cancer (NSCLC) Pembrolizumab medicine.disease Pemetrexed Non squamous Internal medicine Platinum chemotherapy medicine Initial treatment business medicine.drug
Zdroj:	Value in Health. 22:S81
ISSN:	1098-3015
DOI:	10.1016/j.jval.2019.04.255
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::5566ee34b0fa56880de4264dbf5e56ca https://doi.org/10.1016/j.jval.2019.04.255 Zobrazit plný text záznamu Full Text from ScienceDirect